Compare Stocks → The Hard Truth About Investing For Retirement (From Insiders Exposed) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:FLXN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFLXNFlexion Therapeutics$9.12$9.20$4.30▼$13.66$458.93M1.531.18 million shsN/A7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFLXNFlexion Therapeutics0.00%0.00%0.00%0.00%0.00%One trade. One ticker. One week. (Ad)Do you want to target weekly income of up to $2k or more… Starting with just $500... With just one trade per week? Well, then you should click here to see this free training.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationFLXNFlexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFLXNFlexion TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFLXNFlexion Therapeutics$85.55M5.36N/AN/A($0.34) per share-26.82Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFLXNFlexion Therapeutics-$113.71M-$2.01N/AN/AN/A-100.32%N/A-44.26%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthFLXNFlexion TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFLXNFlexion TherapeuticsN/A4.384.05OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFLXNFlexion Therapeutics90.01%Insider OwnershipCompanyInsider OwnershipFLXNFlexion Therapeutics9.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableFLXNFlexion Therapeutics25750.32 million45.73 millionOptionableFLXN HeadlinesSourceHeadlineFlexion awarded contract to revolutionize Head Start’s Data Management Systemfinance.yahoo.com - April 19 at 10:06 AMFlexion Joins AWS Public Sector Partner Program, Enhancing Commitment to Public Sector Software Projectstmcnet.com - April 11 at 8:22 AMVIRI Virios Therapeutics, Inc.seekingalpha.com - April 6 at 11:58 PMSpyre Therapeutics Inc SYREmorningstar.com - February 14 at 2:31 AMPFIZER INC's Net Worthbenzinga.com - February 10 at 6:39 PMFlexion/Extension Fluoroscopy of C-Spine is Inadequatemedscape.com - January 12 at 8:52 AMSpringWorks Therapeutics Stock (NASDAQ:SWTX), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 24 at 2:18 PMFlexion Mobile: Cuts 2023 sales forecast on softer Q3 - ABGnyheter24.se - November 6 at 10:35 AMOppo Unveils Find N3: Foldable Phone with Flexion Hinge and Snapdragon 8 Gen 2newsd.in - October 19 at 11:15 PMFlexion wins MCADS contract to modernize CMS Claims Handling Systembenzinga.com - July 11 at 1:14 AMFlexion achieves Select Tier Status within the AWS Partner Networkfinance.yahoo.com - July 10 at 3:13 PM7 Exercises to Stretch Plantar Flexion Movementyahoo.com - June 10 at 5:59 PMPain Therapeutics conference is taking place in London next weekpharmaphorum.com - June 8 at 3:32 AMFlexion Mobile: Notice of Annual General Meetingprivataaffarer.se - May 31 at 12:46 PM2023-2029 Flexion Tires Market Growth Prospects and Countries Analysis | with 91 Pagesmarketwatch.com - May 16 at 1:43 AMOPPO Find N2 Flip's Flexion Hinge Marks A Breakthrough In Flip Phone Experiencefinance.yahoo.com - May 4 at 10:11 AMProne Leg Flexion Trainers Market Global Outlook and Projection till 2029marketwatch.com - April 28 at 10:21 AMAbdominal Flexion Training Device Market Research & Size Analysis 2023-2028marketwatch.com - April 12 at 6:57 PMProne Leg Flexion Trainers Market 2023 Huge Demand, Growth Opportunities and Expansion by 2031marketwatch.com - April 6 at 4:41 PMGlobal Flexion Tires Market: Future Extrapolations and Emerging Updates for 2023-2027marketwatch.com - March 23 at 4:51 PMOPPO Find N2 Flip: How Flexion Hinge improves flip phone experience - Explainedzeebiz.com - February 28 at 1:06 PMOppo’s new Flexion hinge has made flip phones more practical and crease minimalmsn.com - February 24 at 9:41 AMLateral Flexionhealthline.com - January 22 at 3:36 PMWhat Is Plantar Flexion and Why Is It Important?healthline.com - January 21 at 1:56 PMCompany DescriptionsFlexion TherapeuticsNASDAQ:FLXNFlexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
